Institutional investors purchased a net $6.6 million shares of MNKD during the quarter ended March 2013. This may signal that the smart money is gaining interest in this company as the 18.31% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
| Mutual fund holders | 9.67% |
| Other institutional | 8.64% |
| Individual stakeholders | 42.85% |